A5006055158- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Ocular Oncology and Treatments
- Childhood Cancer Survivors' Quality of Life
- Retinoids in leukemia and cellular processes
- Lymphoma Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Immunodeficiency and Autoimmune Disorders
- BRCA gene mutations in cancer
- Hematological disorders and diagnostics
- Immunotherapy and Immune Responses
- DNA Repair Mechanisms
- Cancer-related gene regulation
- Protein Degradation and Inhibitors
- Peptidase Inhibition and Analysis
- Cutaneous Melanoma Detection and Management
- Genomic variations and chromosomal abnormalities
- MicroRNA in disease regulation
- RNA modifications and cancer
Copenhagen University Hospital
2015-2025
Rigshospitalet
2016-2025
Accreditation Council for Graduate Medical Education
2020
University of Copenhagen
2001-2017
Odense University Hospital
2015
Aalborg University Hospital
2015
Aarhus University Hospital
2015
Université de Montréal
2012
Laboratory of Molecular Genetics
2011
Aberdeen Royal Infirmary
2009
Secondary and therapy-related acute myeloid leukemia (sAML tAML, respectively) remain therapeutic challenges. Still, it is unclear whether their inferior outcome compared with de novo (AML) varies as a result of previous hematologic disease or can be explained by differences in karyotype and/or age.In Danish national population-based study 3,055 unselected patients AML diagnosed from 2000 to 2013, we the frequencies characteristics myelodysplastic syndrome (MDS) -sAML, non-MDS-sAML (chronic...
PURPOSE: To study mutations and loss of heterozygosity (LOH) p53 in therapy-related myelodysplasia (t-MDS) acute myeloid leukemia (t-AML). PATIENTS AND METHODS: Fifty-two unselected patients with t-MDS 25 t-AML were studied by polymerase chain reaction (PCR)–single-strand conformational polymorphism (SSCP) at the DNA level reverse transcriptase (RT)-PCR–SSCP mRNA level, cases aberrant SSCP patterns sequenced. RESULTS: Somatically acquired observed 21 77 or t-AML, 19 these had received...
Abstract The Workshop identified 48 unselected patients with therapy‐related myelodysplastic syndrome or acute myeloid leukemia (t‐MDS/t‐AML) and inv(16), 41 t(15;17) after chemotherapy (CT) and/or radiotherapy (RT) for a malignant nonmalignant disease. primary diseases were: breast cancer, 33 patients; lymphomas, 24 various other solid tumors, 30 diseases, 2 patients. general type of previous therapy was RT only in 10 an inv(16) 12 t(15;17), alkylating agents plus topoisomerase II...
Abstract Myeloid neoplasms (MNs) with germline predisposition have recently been recognized as novel entities in the latest World Health Organization (WHO) classification for MNs. Individuals MNs due to exhibit increased risk development of MNs, mainly acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Setting diagnosis MN is crucial clinical significance since it may tailor therapy, dictate selection donor allogeneic hematopoietic stem cell transplantation (allo-HSCT),...
Abstract Gene amplification is a rare phenomenon in acute leukemia, but recently of specific chromosome bands containing genes rearranged leukemia‐specific balanced translocations has been reported few cases. We detected duplication or band 11q23 with 3–7 copies the MLL gene by fluorescence situ hybridization 12 out 70 unselected patients therapy‐related myelodysplasia myeloid leukemia (17%). In all one case, supernumerary were located to previously unidentified marker chromosomes unbalanced...
Abstract In chronic lymphocytic leukemia, the reliability of next‐generation sequencing (NGS) to detect TP53 variants ≤10% allelic frequency (low‐VAF) is debated. We tested ability 23 such in 41 different laboratories using their NGS method choice. The sensitivity was 85.6%, 94.5%, and 94.8% at 1%, 2%, 3% VAF cut‐off, respectively. While only one false positive (FP) result reported >2% VAF, it more challenging distinguish true <2% from background noise (37 FPs by 9 laboratories)....
Myeloablative conditioning (MAC) and reduced intensity (RIC) regimens are both used before allogeneic haematopoietic stem cell transplantation (allo-HCT) for myelofibrosis (MF). The median age of patients with MF treated allo-HCT is increasing a high non-relapse mortality (NRM), especially to MAC, has increased utilisation lesser intense non-myeloablative (NMA) regimens. NMA as the standard regimen at all centres in Denmark. To describe outcomes highly homogenously treated, population...